Skip to content

Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients

Prevalence and Prognostic Impact of Noncardiac Comorbidities in Heart Failure Outpatients With Preserved and Reduced Ejection Fraction: A Community-Based Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02946476
Acronym
NCC-HF
Enrollment
2314
Registered
2016-10-27
Start date
2009-11-30
Completion date
2014-12-31
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Diastolic, Heart Failure, Systolic

Brief summary

To better understand the public health prognostic impact of noncardiac chronic illnesses, we explored the attributable risk of noncardiac comorbidities on outcomes between heart failure patients with reduced ejection fraction (HFREF) and heart failure patients with preserved ejection fraction (HFpEF) in a large contemporary heart failure (HF) population The adjusted hazard ratio (HR) and the population attributable risk were used to compare the contributions of 15 noncardiac comorbidities to adverse outcome. The comorbidities that contributed to high attributable risk were: anemia, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, and peripheral artery disease. These findings were similar for HFrEF and HFpEF groups. Interaction analysis confirmed similar results.

Interventions

OTHERprognostic impact of non cardiac comorbidities

Sponsors

Ospedale Maggiore Di Trieste
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consecutive heart failure patients with left ventricular ejction fraction available before or within 3 months from the index visit

Exclusion criteria

* We excluded all patients who had severe primary left-sided valvular disease

Design outcomes

Primary

MeasureTime frame
overall mortality2 years

Secondary

MeasureTime frame
First all-cause hospitalization2 years
Heart Failure hospitalization2 years
noncardiovascular hospitalization2 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026